FNL Small Molecule Studies
These studies were acquired from Robert Kinders at Ft. Detrick on the recommendation of Ralph Parchment as a starting point for collecting data at the very beginning of the project and are a good representation of a clinical trials data model.
NCATS - Greg Tawa
Pre-medical Cancer Immunotherapy Network for Canine Trials (PRECINCT)
https://dctd.cancer.gov/NewsEvents/20190327_canine_immunotherapy.htm
http://grantome.com/grant/NIH/U24-CA224122-01
https://deainfo.nci.nih.gov/advisory/bsa/1016/1_CanineTrials.pdf (Description of UM1/U24 grants and relationships)
U24 Holder - Data Coordinating Center for U01 Holders
in cooperation with NCI COP and NCI program staff:
•Help develop and implement clinical studies
•Assist in standardization of clinical and laboratory protocols
•Manage clinical and correlative data and provide statistical support
•Facilitate sharing of agent, specimens and data
Institution | Project Leader(s) | Canine Cancer(s) |
U Penn | Nicola Mason/Kathleen Propert | U24 coordinating center |
UM1 Holders - Clinical Data
•Conduct canine clinical trials using immunotherapeutic agents and novel combinations
•Correlative studies to characterize and understand the cellular and molecular mechanisms that determine response (or non-response)
Institution | Project Leader(s) | Canine Cancer(s) |
Colorado State U | Steven Dow/Cheryl London | Osteosarcoma, novel immunotherapy combinations |
U of Alabama at Birmingham | MR Chambers | Glioma, immuno-neurotherapeutics |
U of Minnesota | Grace Elizabeth Pluhar | Glioma, immunotherapy combinations |
UC Davis | Robert Canter/Robert Rebhun | Melanoma and osteosarcoma, NK immunotherapy |
Tufts U | Cheryl London/Kristy Richards | B-cell lymphoma, immunotherapy combinations |
P30 Grant Holders - Genomic Data
In 2016 the NCI awarded 8 1-year supplements to support research in canine immunotherapy via collaborations between NCI-designated cancer centers and veterinary medical colleges
Goals included:
•Sequence (whole exome and RNAseq) of at least 25 canine tumors and their normal controls in one or more of the following tumors: B-cell lymphoma, glioma, osteosarcoma, melanoma, bladder cancer and mammary cancer
•Determine mutational load
•Characterize potential neoantigens that can bind canine MHC complexes
•Characterize T lymphocyte numbers and subsets and other relevant aspects of the tumor microenvironment in canine tumors
Institution | Project Leader(s) | Canine Cancer(s) |
Baylor/U Florida Vet Med/Texas A&M/Tech U Denmark | Jonathan Levitt, PhD/Alan Herron, DVM | bladder, mammary, melanoma |
U Colorado/Colorado State U Vet | Jill Slansky, PhD/Steven Dow, DVM, PhD | B-cell lymphoma |
DFCI-HCC/Tufts U Vet Med | Katherine Janeway, MD/Cheryl London, DVM | osteosarcoma |
Purdue U/Duke U | Deborah Knapp, DVM/H. Kim Lyerly, MD | bladder |
Roswell Park/Cornell U Vet Med | Richard Koya, MD PhD/Kristy Richards, MD PhD | B-cell lymphoma |
UC Davis/UC Davis Vet Med | Arta Monjazeb, MD PhD | glioma, melanoma, osteosarcoma |
Ohio State U/OSU Vet Med/TGEN | Peter Shields, MD/Jeffrey Trent, PhD | melanoma, osteosarcoma |
MD Anderson/Texas A&M | Amy Heimberger, MD/Jonathan Levine, DVM | glioma |
P30 Grant holder:
Richard C. Koya, MD, PhD (email of 12/11/18):
Associate Director of the Center for Immunotherapy
Director of the Vector Development & Production Facility
Associate Professor of Oncology and Immunology
Roswell Park Comprehensive Cancer Center
Center for Immunotherapy
Elm and Carlton Streets, CCC-419
Buffalo, NY, 14263
Phone: (716) 845-1300, ext. 6582
Email: richard.koya@roswellpark.org
Bioinformatician
Sebastiano Battaglia, PhD
Assistant Professor of Oncology
Center For Immunotherapy
Assistant Member
Dept. of Cancer Genetic and Genomics
Roswell Park Comprehensive Cancer Center
Elm and Carlton sts.
14263, Buffalo, NY, USAA
p: +1 716 845 2300 ext. 5559
e: sebastiano.battaglia@roswellpark.org
P30 Grant holder
Deborah Knapp (email of 12/11/18):
Dhawan D, Hahn NM, Ramos-Vara JA, Knapp DW. Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer. PLoS Genet. 2018 Aug 8;14(8):e1007571. doi: 10.1371/journal.pgen.1007571. eCollection 2018 Aug. PMID: 30089113
Dhawan D, Paoloni M, Shukradas S, Choudhury DR, Craig BA, Ramos-Vara JA, Hahn N, Bonney PL, Khanna C, Knapp DW. Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer. PLoS One. 2015 Sep 9;10(9):e0136688. doi: 10.1371/journal.pone.0136688. eCollection 2015. PMID: 26352142
